Immunotherapy after surgery for esophageal cancer with complete response
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether an immunotherapy drug called toripalimab, given after surgery, can help prevent esophageal cancer from returning in people whose cancer completely disappeared after chemo or radiation and surgery. If you already had a complete response, this treatment might lower the risk of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had stage II or III esophageal cancer that was confirmed to be squamous cell carcinoma.
- You completed chemotherapy or radiation before your surgery, and then had surgery to remove the tumor.
- After surgery, no cancer cells were found in the removed tumor or lymph nodes (called a complete response).
- You have not had any additional cancer treatment after your surgery.
- You are generally well enough to look after yourself and are not bedridden.
- Your blood counts, liver, and kidney function are within acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, sacituzumab tirumotecan and toripalimab, given before surgery for esophageal cancer that has spread nearby but is still removable. The goal is to see if this combination shrinks the tumor and improves outcomes.
This trial tests whether continuing immunotherapy (toripalimab) after surgery helps prevent esophageal cancer from coming back. It is for people who already had surgery for squamous cell esophageal cancer after receiving immunotherapy plus chemotherapy before surgery.
This trial tests a combination of an immunotherapy drug (toripalimab), chemotherapy, and low-dose radiation for people with esophageal cancer that did not shrink after initial chemotherapy and immunotherapy. The goal is to see if this new combination can help control the cancer before surgery.
This trial tests a new immunotherapy drug called toripalimab, given before, during, and after standard radiation and chemotherapy for esophageal cancer that hasn't spread. The goal is to see if adding this drug can improve outcomes for patients.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemoradiation before surgery helps people with a type of esophageal cancer. It is for patients whose cancer has not spread to other organs and who have not had treatment before.
This trial tests whether continuing a type of immunotherapy (toripalimab) after standard chemoradiation helps keep advanced esophageal cancer from growing, compared to just watching and waiting. If you've already completed initial treatment without the cancer getting worse, this study might help you stay stable longer.
Hear when a new Esophageal Squamous Cell Carcinoma Stage II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.